Pipelines

Home > Pipelines > CNS disorders

CNS disorders

NBHL has expanded its R&D program to focus on CNS disorders associated with Alzheimer’s disease, such as insomnia and night wandering. There is an unmet need for more effective treatment for insomnia and improvement in sleep maintenance in patients with Alzheimer’s disease. It has been estimated that insomnia affects almost half of patients with Alzheimer’s disease. NBHL has explored new compounds to address the problem of disrupted sleep or waking too early.

CK1 δ/ε dual kinase inhibitor for insomnia associated with dementia (P005)

NBHL has discovered the structure of a casein kinase 1δ/ε (CK1δ/ε) inhibitor for insomnia. The CK1 kinases are involved in circadian rhythm and a genetic mutation in human CK1δ causes a problem with circadian rhythm. In a sleep-wake animal model, we showed that a single administration of NBHL’s CK1 δ/ε kinase inhibitor promoted sleep and augmented non-rapid eye movement sleep significantly. Patents for the novel compound have been issued in Japan, Europe and the USA, and patent applications have been filed in other major countries. We are planning to enter the clinical stage of development at the end of 2017.